These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo. Sita TL; Kouri FM; Hurley LA; Merkel TJ; Chalastanis A; May JL; Ghelfi ST; Cole LE; Cayton TC; Barnaby SN; Sprangers AJ; Savalia N; James CD; Lee A; Mirkin CA; Stegh AH Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4129-4134. PubMed ID: 28373576 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, Physicochemical, and Biological Evaluation of Spherical Nucleic Acids for RNAi-Based Therapy in Glioblastoma. Tommasini-Ghelfi S; Lee A; Mirkin CA; Stegh AH Methods Mol Biol; 2019; 1974():371-391. PubMed ID: 31099015 [TBL] [Abstract][Full Text] [Related]
6. miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Kouri FM; Hurley LA; Daniel WL; Day ES; Hua Y; Hao L; Peng CY; Merkel TJ; Queisser MA; Ritner C; Zhang H; James CD; Sznajder JI; Chin L; Giljohann DA; Kessler JA; Peter ME; Mirkin CA; Stegh AH Genes Dev; 2015 Apr; 29(7):732-45. PubMed ID: 25838542 [TBL] [Abstract][Full Text] [Related]
7. Spherical Nucleic Acids as Precision Therapeutics for the Treatment of Cancer-From Bench to Bedside. Mahajan AS; Stegh AH Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406387 [TBL] [Abstract][Full Text] [Related]
8. In Vivo Behavior of Ultrasmall Spherical Nucleic Acids. Callmann CE; Vasher MK; Das A; Kusmierz CD; Mirkin CA Small; 2023 Jun; 19(24):e2300097. PubMed ID: 36905236 [TBL] [Abstract][Full Text] [Related]
9. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials. Lozada-Delgado EL; Grafals-Ruiz N; Vivas-Mejía PE Life Sci; 2017 Nov; 188():26-36. PubMed ID: 28864225 [TBL] [Abstract][Full Text] [Related]
10. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661 [TBL] [Abstract][Full Text] [Related]
11. miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics. Kouri FM; Ritner C; Stegh AH Cell Cycle; 2015; 14(24):3794-800. PubMed ID: 26506113 [TBL] [Abstract][Full Text] [Related]
12. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression. Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962 [TBL] [Abstract][Full Text] [Related]
13. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Stegh AH; Kim H; Bachoo RM; Forloney KL; Zhang J; Schulze H; Park K; Hannon GJ; Yuan J; Louis DN; DePinho RA; Chin L Genes Dev; 2007 Jan; 21(1):98-111. PubMed ID: 17210792 [TBL] [Abstract][Full Text] [Related]
15. Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial. Lim J; Park Y; Ahn JW; Sim J; Kang SJ; Hwang S; Chun J; Choi H; Kim SH; Chun DH; Sung KS; Kwack K; Cho K PLoS One; 2021; 16(3):e0247293. PubMed ID: 33690665 [TBL] [Abstract][Full Text] [Related]
16. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Stegh AH; Kesari S; Mahoney JE; Jenq HT; Forloney KL; Protopopov A; Louis DN; Chin L; DePinho RA Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10703-8. PubMed ID: 18669646 [TBL] [Abstract][Full Text] [Related]
17. siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown. Randeria PS; Seeger MA; Wang XQ; Wilson H; Shipp D; Mirkin CA; Paller AS Proc Natl Acad Sci U S A; 2015 May; 112(18):5573-8. PubMed ID: 25902507 [TBL] [Abstract][Full Text] [Related]
18. Molecular Evolution of Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054 [TBL] [Abstract][Full Text] [Related]
19. What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator. Stegh AH; Chin L; Louis DN; DePinho RA Cell Cycle; 2008 Sep; 7(18):2833-9. PubMed ID: 18769159 [TBL] [Abstract][Full Text] [Related]
20. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma. Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]